other material
confidence high
sentiment positive
materiality 0.90
CG Oncology PIVOT-006 Phase 3 wins: 68% recurrence risk cut (HR 0.32) in NMIBC
CG Oncology, Inc.
- Cretostimogene cut recurrence risk 68% vs control in adjuvant intermediate-risk/high-grade Ta ≤3cm NMIBC; HR 0.32 (95% CI 0.23-0.45; p<0.0001), median follow-up 17 months.
- No Grade 3 or greater treatment-related adverse events and no treatment-related discontinuations; safety consistent with prior studies.
- Initial BLA in BCG-unresponsive NMIBC broadened per FDA feedback to include high-grade papillary-only disease plus CIS; completion now expected by end of March 2027.
- Second BLA in intermediate-risk and high-grade Ta NMIBC planned for Q2 2027; ~50,000 US patients in this population have no FDA-approved adjuvant option.
- Topline results to be presented as a late-breaking podium at the Society of Urologic Oncology Annual Meeting on December 2, 2026.
Featured in Daily 8-K Digest
Selected #9 for 2026-11-16.
Read digest